These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26574910)

  • 1. Cost-effectiveness analysis of antiviral treatment in the management of seasonal influenza A: point-of-care rapid test versus clinical judgment.
    Nshimyumukiza L; Douville X; Fournier D; Duplantie J; Daher RK; Charlebois I; Longtin J; Papenburg J; Guay M; Boissinot M; Bergeron MG; Boudreau D; Gagné C; Rousseau F; Reinharz D
    Influenza Other Respir Viruses; 2016 Mar; 10(2):113-21. PubMed ID: 26574910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Bellantonio S; Rose DN
    Ann Intern Med; 2003 Sep; 139(5 Pt 1):321-9. PubMed ID: 12965940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
    Shen K; Xiong T; Tan SC; Wu J
    PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of influenza symptoms in healthy adults.
    Rothberg MB; He S; Rose DN
    J Gen Intern Med; 2003 Oct; 18(10):808-15. PubMed ID: 14521643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Fisher D; Kelly B; Rose DN
    Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.
    Lee BY; McGlone SM; Bailey RR; Wiringa AE; Zimmer SM; Smith KJ; Zimmerman RK
    PLoS One; 2010 Jun; 5(6):e11284. PubMed ID: 20585642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
    Lee PY; Matchar DB; Clements DA; Huber J; Hamilton JD; Peterson ED
    Ann Intern Med; 2002 Aug; 137(4):225-31. PubMed ID: 12186512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.
    You JH; Chan ES; Leung MY; Ip M; Lee NL
    PLoS One; 2012; 7(3):e33123. PubMed ID: 22479363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
    O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
    Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza.
    Lavelle TA; Uyeki TM; Prosser LA
    J Pediatr; 2012 Jan; 160(1):67-73.e6. PubMed ID: 21917267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis.
    Milne GJ; Halder N; Kelso JK
    PLoS One; 2013; 8(4):e61504. PubMed ID: 23585906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
    Postma MJ; Novak A; Scheijbeler HW; Gyldmark M; van Genugten ML; Wilschut JC
    Pharmacoeconomics; 2007; 25(6):497-509. PubMed ID: 17523754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
    Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
    Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.